PUBLICATIONS

Research Articles

  1. *Miyake K, Costa Cruz PH, Nagatomo I, Kato Y, Motooka D, Satoh S, Adachi Y, Takeda Y, *Kawahara Y, *Kumanogoh A. A cancer-associated METTL14 mutation induces aberrant m6A modification affecting tumor growth. Cell Reports, 42(7), 112688, 2023. (*Co-corresponding authors) 研究内容紹介
  2. #Xing Y, #,*Nakahama T, Wu Y, Inoue M, Kim JI, Todo H, Shibuya T, Kato Y, *Kawahara Y. RNA editing of AZIN1 coding sites is catalyzed by ADAR1 p150 after splicing. Journal of Biological Chemistry, 299(7), 104840, 2023. (#Co-first authors, *Co-corresponding authors)
  3. Yoshinaga M, Han K, Morgens DW, Horii T, Kobayashi R, Tsuruyama T, Hia F, Yasukura S, Kajiya A, Cai T, Cruz PHC, Vandenbon A, Suzuki Y, Kawahara Y, Hatada I, Bassik MC, Takeuchi O. The N6-methyladenosine methyltransferase METTL16 enables erythropoiesis through safeguarding genome integrity. Nature Communications, 13, 6435, 2022.
  4. Sugihara R, *Kato Y, Mori T, Kawahara Y. Alignment of single-cell trajectory trees with CAPITAL. Nature Communications, 13, 5972, 2022. 研究内容紹介
  5. #Inoue M, #Nakahama T, Yamasaki R, Shibuya T, Kim JI, Todo H, Xing Y, Kato Y, Morii E, *Kawahara Y. An Aicardi-Goutières syndrome–causative point mutation in Adar1 gene invokes multiorgan inflammation and late-onset encephalopathy in mice. The Journal of Immunology, 207(12): 3016-3027, 2021. (#Co-first authors)
  6. Nakahama T, Kato Y, Shibuya T, Inoue M, Kim JI, Vongpipatana T, Todo H, Xing Y, and *Kawahara Y. Mutations in the adenosine deaminase ADAR1 that prevent endogenous Z-RNA binding induce Aicardi-Goutières syndrome–like encephalopathy. Immunity, 54: 1976-1988, 2021. Preview 研究内容紹介
  7. Uyeda A, Quan L, Kato Y, Muramatsu N, Tanabe S, Sakai K, Ichinohe N, Kawahara Y, Suzuki, T, *Muramatsu R. Dimethylarginine dimethylaminophdrolase 1 as a novel regulator of oligodendrocyte differentiation in the central nervous system remyelination. Glia, 69(11): 2591-2604, 2021.
  8. #Kim JI, #Nakahama T, Yamasaki R, Costa Cruz PH, Vongpipatana T, Inoue M, Kanou N, Xing Y, Todo H, Shibuya T, Kato Y, *Kawahara Y. RNA editing at a limited number of sites is sufficient to prevent MDA5 activation in the mouse brain. PLOS Genetics, 17(5): e1009516, 2021. (#Co-first authors)
  9. Ito M, Muramatsu R, Kato Y, Sharma B, Uyeda A, Tanabe S, Fujimura H, Kidoya H, Takakura N, Kawahara Y, Takao M, Mochizuki H, Fukamizu A, Yamashita T. Age-dependent decline in remyelination capacity is mediated by apelin–APJ signaling. Nature Aging, 1: 284-294, 2021.
  10. #Vongpipatana T, #,*Nakahama T, Shibuya T, Kato Y, *Kawahara Y. ADAR1 regulates early T cell development via MDA5-dependent and -independent pathways. The Journal of Immunology, 204(8): 2156-2168, 2020. (#Co-first authors)
  11. Shimmura K, *Kato Y, Kawahara Y. Bivartect: accurate and memory-saving breakpoint detection by direct read comparison. Bioinformatics, 36(9): 2725-2730, 2020.
  12. Costa Cruz PH, Kato Y, Nakahama T, Shibuya T, *Kawahara Y. A comparative analysis of ADAR mutant mice reveals site-specific regulation of RNA editing. RNA, 26(4): 454-469, 2020.
  13. *Nakahama T, Kato Y, Kim JI, Vongpipatana T, Suzuki Y, Walkley CR, *Kawahara Y. ADAR1‐mediated RNA editing is required for thymic self‐tolerance and inhibition of autoimmunity. EMBO Reports, 19, e46303, 2018. News & Views
  14. Oshima T, Ishiguro K, Suzuki T, *Kawahara Y. Quantification of methylation efficiency at a specific N6-methyladenosine position in rRNA by using BNA probes. Chemical Communications, 54(69); 9627-9630, 2018.
  15. Nakasone A, Muramatsu R, Kato Y, Kawahara Y, Yamashita T. Myotube-derived factor promotes oligodendrocyte precursor cell proliferation. Biochemical and Biophysical Research Communications, 500(3); 609-613, 2018.
  16. Gallego A, Hartasánchez DA, Brasó-Vives M, Garcia-Ramallo E, Lopez-Valenzuela M, Baena N, Guitart M, Fernández-Bellon H, Kondova I, Bontrop R, Kawahara Y, Espinosa-Parrilla Y. RNA editing independently occurs at three mir-376a-1 sites and may compromise the stability of the microRNA hairpin. Gene, 628; 109-116, 2017.
  17. Uemura Y, Oshima T, Yamamoto M, Reyes CJ, Costa Cruz PH, Shibuya T, *Kawahara Y. Matrin3 binds directly to intronic pyrimidine-rich sequences and controls alternative splicing. Genes to Cells, 22(9); 785-798, 2017.
  18. Kanemitsu Y, Fujitani M, Fujita Y, Zhang S, Su YQ, Kawahara Y, Yamashita T. The RNA-binding protein MARF1 promotes cortical neurogenesis through its RNase activity domain. Scientific Reports, 7(1); 1155, 2017.
  19. Miyake K, Ohta T, Nakayama H, Doe N, Terao Y, Oiki E, Nagatomo I, Yamashita Y, Abe T, Nishikura K, Kumanogoh A, Hashimoto K, *Kawahara Y. CAPS1 RNA Editing Promotes Dense Core Vesicle Exocytosis. Cell Reports, 17; 2004-2014, 2016. F1000Prime 研究内容紹介
  20. Li Q, Yokoshi M, Okada H, *Kawahara Y. The cleavage pattern of TDP-43 determines its rate of clearance and cytotoxicity. Nature Communications, 6; 6183, 2015. 研究内容紹介
  21. Li Q, Uemura Y, *Kawahara Y. Cross-Linking and Immunopresipitation of Nuclear RNA-Binding Proteins. Methods in Molecular Biology,1262; 247-263, 2015.
  22. #Yokoshi M, #Li Q, #Yamamoto M, Okada H, Suzuki Y, *Kawahara Y. Direct binding of Ataxin-2 to distinct elements in 3’UTRs promotes mRNA stability and protein expression. Molecular Cell, 55(2); 186-198, 2014. (#Co-first authors) 研究内容紹介
  23. Nakahama T, Hanieh H, Nguyen NT, Chinen I, Ripley B, Millrine D, Lee S, Nyati KK, Dubey PK, Chowdhury K, Kawahara Y, Kishimoto T. Aryl hydrocarbon receptor-mediated induction of the miR-132/212 cluster promotes TH17 cell differentiation. Proceedings of the National Academy of Sciences U. S. A., 110(29); 11964-11969, 2013.
  24. Matsumoto S, Sakata Y, Nakatani D, Suna S, Usami M, Hara M, Kitamura T, Hamasaki T, Nanto S, *Kawahara Y, *Komuro I. Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circulation Research, 113(3); 322-326, 2013. (*Co-corresponding authors)
  25. Matsumoto S, Sakata Y, Nakatani D, Suna S, Mizuno H, Shimizu M, Usami M, Sasaki T, Sato H, Kawahara Y, Hamasaki T, Nanto S, Hori M and Komuro I. A Subset of Circulating MicroRNAs are Predictive for Cardiac Death After Discharge for Acute Myocardial Infarction. Biochemical and Biophysical Research Communications, 2012 427(2); 280-284, 2012.
  26. Kin K, Miyagawa S, Fukushima S, Shirakawa Y, Torikai K, Shimamura K, Kawahara Y, Daimon T, Kuratani T, Sawa Y. Tissue- and plasma-specific microRNA signatures for atherosclerotic abdominal aortic aneurysm. Journal of the American Heart Association, 1; e000745, 2012.
  27. *Kawahara Y. Quantification of adenosine-to-inosine editing of microRNAs using a conventional method. Nature Protocols, 7(7); 1426-1437, 2012.
  28. *Kawahara Y and Mieda-Sato I. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proceedings of the National Academy of Sciences U. S. A., 109 (9); 3347-3352, 2012. (*Corresponding author)

Review Articles & Books

  1. Nakahama T, *Kawahara Y. The RNA-editing enzyme ADAR1: a regulatory hub that tunes multiple dsRNA-sensing pathways. International Immunology, 35(3): 123-133, 2023.
  2. Nakahama T, *Kawahara Y. Deciphering the Biological Significance of ADAR1–Z-RNA Interactions. International Journal of Molecular Sciences, 22(21): 11435, 2021.
  3. Costa Cruz PH, *Kawahara Y. RNA editing in neurological and neurodegenerative disorders. Methods in Molecular Biology, 2181: 309-330, 2020.
  4. Nakahama T, *Kawahara Y. Adenosine-to-inosine RNA editing in the immune system: friend or foe? Cellular and Molecular Life Sciences, 77(15): 2931-2948, 2020
  5. *Kawahara Y, Human diseases caused by germline and somatic abnormalities in microRNA and microRNA-related genes. Congenital Anomalies, 54(1); 12-21, 2014.
  6. Valente L, Kawahara Y, Zinshteyn B, Iizasa H and Nishikura K. Post-transcriptional gene regulation by an Editor: ADAR and its role in RNA Editing. Post-transcriptional gene regulation: RNA processing in eukaryotes. (Ed. Jane Wu) Wiley-VCH book, 41-82, 2013.

Japanese Reviews

  1. 河原行郎. RNA編集を応用した疾患治療の展望. Clinical Neuroscience, 41(5): 684-686, 2023.
  2. 中濱泰祐, 河原行郎. RNA制御とI型インターフェロノパシー. 実験医学(増刊), 40(15): 2505-2512, 2022.
  3. 河原行郎. RNA編集 -生理的な働きと遺伝子改変技術への応用-. 実験医学(増刊), 40(12): 1952-1958, 2022.
  4. 河原行郎. 左巻きRNAを認識する自然免疫機構. 臨床免疫・アレルギー科, 78(1): 111-117, 2022.
  5. 中濱泰祐, 河原行郎. RNAのイノシン化修飾の破綻はエカルディ・グティエール症候群様症状を引き起こす. 臨床免疫・アレルギー科, 77(6): 737-743, 2022.
  6. 中濱泰祐, 河原行郎. RNAの巻き方を感知する自己免疫システム. 実験医学, 40(4): 544-549, 2022.
  7. 河原行郎. RNA編集を応用した核酸医薬開発への展望. 実験医学(増刊), 39(17): 2772-2778, 2021.
  8. 河原行郎. エピトランスクリプトーム. 炎症と免疫, 28(6): 546-550, 2020.
  9. 河原行郎. CLIP法とその改良法によるタンパク質結合RNAの高解像度解析. 実験医学(別冊), 149-158, 2016.
  10. 三宅浩太郎, 中濱泰祐, 河原行郎. 自己免疫疾患とRNA編集. 実験医学(増刊), 33(20): 3339-3344, 2015.
  11. 河原行郎. 神経疾患をmicroRNAで診断する. Clinical Neuroscience, 33(11): 1302-1304, 2015.
  12. 余越萌, 河原行郎. マイクロRNA. 生体の科学, 66(5): 478-479, 2015.
  13. 河原行郎. 神経変性疾患の発症メカニズムUp-to-Date. BIO Clinica, 30(7): 705-708, 2015.
  14. 余越萌, 河原行郎. RNA代謝異常を介した神経変性疾患の発症病態. ファルマシア, 51(1): 37-41, 2015.
  15. 余越萌, 河原行郎. 神経変性疾患関連タンパク質Ataxin-2は3’非翻訳領域にある特定の配列に直接結合することによって、mRNAの安定性を促進しタンパク質発現を増加させる. 新着論文レビュー, e9044, 2014
  16. 植村有里・河原行郎. RNA代謝と神経変性. Brain Medical, 26(3): 209-215, 2014.
  17. 河原行郎・塩見美喜子. RNA疾患研究の新展開. Medical Science Digest 臨時増刊号 RNA疾患 (河原行郎・塩見美喜子編輯), 40(7): 324-325, 2014.
  18. 河原行郎. ノンコーディングRNAと神経変性疾患. 医学のあゆみ, 247(5): 421-426, 2013.
  19. 河原行郎. 筋萎縮性側索硬化症とRNA結合タンパク質. 領域融合レビュー, 2: e010, 2013.
  20. 余越萌, 河原行郎. microRNAの修飾とその機能. 実験医学(増刊), 31(7): 1124-1131, 2013.
  21. 河原行郎. microRNA. 分子脳血管病. 11(4): 431-434, 2012.
  22. 河原行郎. マイクロRNA. 分子精神医学. 11(3): 172-177, 2011.